EDSA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
5.5M
+28.5%
4.3M
+83.5%
2.3M
-5.2%
2.5M
+29.8%
1.9M
R&D
4.0M
+43.0%
2.8M
+146.0%
1.1M
-8.2%
1.2M
+30.5%
939.1K
SG&A
1.6M
+2.1%
1.5M
+25.7%
1.2M
-2.3%
1.2M
+29.0%
964.7K
Operating Income
-5519549
-28.5%
-4296994
-83.5%
-2341383
+5.2%
-2470248
-29.8%
-1903743
EBITDA
-5493905
-28.6%
-4271122
-84.4%
-2315923
+5.3%
-2444380
-30.2%
-1877956
Net Income
-5407611
-28.2%
-4218332
-87.7%
-2247669
-0.9%
-2228358
-27.4%
-1749464
EPS (Basic)
$-0.60
-22.4%
$-0.49
-75.0%
$-0.28
+12.5%
$-0.32
-28.0%
$-0.25
EPS (Diluted)
$-0.60
-22.4%
$-0.49
-75.0%
$-0.28
+12.5%
$-0.32
-28.0%
$-0.25
Shares (Diluted)
9.0M
+5.5%
8.5M
+7.1%
8.0M
+13.4%
7.0M
+0.2%
7.0M
Edesa Biotech, Inc. Common Shares (EDSA) โ€” Financials